These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 37607620)

  • 21. Fluorescence polarization assay for the identification and evaluation of inhibitors at YAP-TEAD protein-protein interface 3.
    Zhou W; Li Y; Song J; Li C
    Anal Biochem; 2019 Dec; 586():113413. PubMed ID: 31479631
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Antiproliferative and Antimigratory Effects of a Novel YAP-TEAD Interaction Inhibitor Identified Using in Silico Molecular Docking.
    Smith SA; Sessions RB; Shoemark DK; Williams C; Ebrahimighaei R; McNeill MC; Crump MP; McKay TR; Harris G; Newby AC; Bond M
    J Med Chem; 2019 Feb; 62(3):1291-1305. PubMed ID: 30640473
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Discovery of a cryptic site at the interface 2 of TEAD - Towards a new family of YAP/TAZ-TEAD inhibitors.
    Sturbaut M; Bailly F; Coevoet M; Sileo P; Pugniere M; Liberelle M; Magnez R; Thuru X; Chartier-Harlin MC; Melnyk P; Gelin M; Allemand F; Guichou JF; Cotelle P
    Eur J Med Chem; 2021 Dec; 226():113835. PubMed ID: 34509860
    [TBL] [Abstract][Full Text] [Related]  

  • 24. YAP/TEAD involvement in resistance to paclitaxel chemotherapy in lung cancer.
    Brosseau S; Abreu P; Bouchez C; Charon L; Kieffer Y; Gentric G; Picant V; Veith I; Camonis J; Descroix S; Mechta-Grigoriou F; Parrini MC; Zalcman G
    Mol Cell Biochem; 2024 Mar; ():. PubMed ID: 38427166
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HepaRG culture in tethered spheroids as an in vitro three-dimensional model for drug safety screening.
    Wang Z; Luo X; Anene-Nzelu C; Yu Y; Hong X; Singh NH; Xia L; Liu S; Yu H
    J Appl Toxicol; 2015 Aug; 35(8):909-17. PubMed ID: 25512232
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting Hippo pathway by specific interruption of YAP-TEAD interaction using cyclic YAP-like peptides.
    Zhou Z; Hu T; Xu Z; Lin Z; Zhang Z; Feng T; Zhu L; Rong Y; Shen H; Luk JM; Zhang X; Qin N
    FASEB J; 2015 Feb; 29(2):724-32. PubMed ID: 25384421
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Establishment of transgenic lines to monitor and manipulate Yap/Taz-Tead activity in zebrafish reveals both evolutionarily conserved and divergent functions of the Hippo pathway.
    Miesfeld JB; Link BA
    Mech Dev; 2014 Aug; 133():177-88. PubMed ID: 24560909
    [TBL] [Abstract][Full Text] [Related]  

  • 28. YAP-TEAD mediates PPAR α-induced hepatomegaly and liver regeneration in mice.
    Fan S; Gao Y; Qu A; Jiang Y; Li H; Xie G; Yao X; Yang X; Zhu S; Yagai T; Tian J; Wang R; Gonzalez FJ; Huang M; Bi H
    Hepatology; 2022 Jan; 75(1):74-88. PubMed ID: 34387904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Identification of a derivative of the alkaloid emetine as an inhibitor of the YAP-TEAD interaction and its potential as an anticancer agent.
    Sekine S; Takase S; Hayase R; Noritsugu K; Maemoto Y; Ichikawa Y; Ogawa K; Kondoh Y; Osada H; Yoshida M; Ito A
    Biosci Biotechnol Biochem; 2023 Apr; 87(5):501-510. PubMed ID: 36809780
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the YAP-TEAD interaction interface for therapeutic intervention in glioblastoma.
    Saunders JT; Holmes B; Benavides-Serrato A; Kumar S; Nishimura RN; Gera J
    J Neurooncol; 2021 Apr; 152(2):217-231. PubMed ID: 33511508
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Human hepatocytes in primary culture: the choice to investigate drug metabolism in man.
    Gómez-Lechón MJ; Donato MT; Castell JV; Jover R
    Curr Drug Metab; 2004 Oct; 5(5):443-62. PubMed ID: 15544436
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dissection of the interaction between the intrinsically disordered YAP protein and the transcription factor TEAD.
    Mesrouze Y; Bokhovchuk F; Meyerhofer M; Fontana P; Zimmermann C; Martin T; Delaunay C; Erdmann D; Schmelzle T; Chène P
    Elife; 2017 Apr; 6():. PubMed ID: 28430104
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RGD density along with substrate stiffness regulate hPSC hepatocyte functionality through YAP signalling.
    Blackford SJI; Yu TTL; Norman MDA; Syanda AM; Manolakakis M; Lachowski D; Yan Z; Guo Y; Garitta E; Riccio F; Jowett GM; Ng SS; Vernia S; Del Río Hernández AE; Gentleman E; Rashid ST
    Biomaterials; 2023 Feb; 293():121982. PubMed ID: 36640555
    [TBL] [Abstract][Full Text] [Related]  

  • 34. An Automated Multiplexed Hepatotoxicity and CYP Induction Assay Using HepaRG Cells in 2D and 3D.
    Ott LM; Ramachandran K; Stehno-Bittel L
    SLAS Discov; 2017 Jun; 22(5):614-625. PubMed ID: 28346810
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Dexamethasone-Induced Liver Enlargement Is Related to PXR/YAP Activation and Lipid Accumulation but Not Hepatocyte Proliferation.
    Jiao T; Yao X; Zhao Y; Zhou Y; Gao Y; Fan S; Chen P; Li X; Jiang Y; Yang X; Gonzalez FJ; Huang M; Bi H
    Drug Metab Dispos; 2020 Sep; 48(9):830-839. PubMed ID: 32561593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homeobox A4 suppresses vascular remodeling by repressing YAP/TEAD transcriptional activity.
    Kimura M; Horie T; Baba O; Ide Y; Tsuji S; Ruiz Rodriguez R; Watanabe T; Yamasaki T; Otani C; Xu S; Miyasaka Y; Nakashima Y; Kimura T; Ono K
    EMBO Rep; 2020 Apr; 21(4):e48389. PubMed ID: 32147946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Progress with YAP/TAZ-TEAD inhibitors: a patent review (2018-present).
    Zagiel B; Melnyk P; Cotelle P
    Expert Opin Ther Pat; 2022 Aug; 32(8):899-912. PubMed ID: 35768160
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The YAP/TEAD Axis as a New Therapeutic Target in Osteosarcoma: Effect of Verteporfin and CA3 on Primary Tumor Growth.
    Morice S; Mullard M; Brion R; Dupuy M; Renault S; Tesfaye R; Brounais-Le Royer B; Ory B; Redini F; Verrecchia F
    Cancers (Basel); 2020 Dec; 12(12):. PubMed ID: 33419295
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Identification of Celastrol as a Novel YAP-TEAD Inhibitor for Cancer Therapy by High Throughput Screening with Ultrasensitive
    Nouri K; Azad T; Ling M; Janse van Rensburg HJ; Pipchuk A; Shen H; Hao Y; Zhang J; Yang X
    Cancers (Basel); 2019 Oct; 11(10):. PubMed ID: 31635084
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cytochrome P450 induction in rat hepatocytes assessed by quantitative real-time reverse-transcription polymerase chain reaction and the RNA invasive cleavage assay.
    Burczynski ME; McMillian M; Parker JB; Bryant S; Leone A; Grant ER; Thorne JM; Zhong Z; Zivin RA; Johnson MD
    Drug Metab Dispos; 2001 Sep; 29(9):1243-50. PubMed ID: 11502735
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.